- MFG # N/A
- UPC # 036733007085
Nutritional support for insulin function and body metabolism.
Any mature individuals with weight problems or individuals with chelation requirements for cardiovascular disorders have components of the Metabolic Syndrome X. Syndrome X affects about 70 million Americans. Syndrome X is the variable combination of obesity‚ abnormal blood cholesterol (dyslipidemia) and high blood pressure‚ linked by underlying resistance to the hormone insulin. Multipronged‚ synergistic‚ metabolic and lifestyle approaches are required to combat the multiple components of Syndrome X. Some of the components of Syndrome X may require appropriate drug treatments.
Syndrome X is often associated with excessive secretion of insulin. The syndrome was first described by Reaven in 1998‚ but its principal component of obesity was not initially emphasized. Retrospective data from the National Health Nutritional Survey‚ for the period 1988 to 1994‚ implied that 47-million Americans had Metabolic Syndrome. The current prevalence of Syndrome X may now be one in every four or five adults
in the United States population. So common and so pernicious are the negative health outcomes of Metabolic Syndrome X that it qualifies as the number-one public health problem facing several Western societies.
Although the Metabolic Syndrome X is identified as a major cause of cardiovascular disease‚ it is less apparent that it increases deaths and disabilities from all causes‚ and it underlies female reproductive disorders‚ polycystic ovary syndrome (PCOS)‚ non-alcoholic fatty-liver disease‚ non-alcoholic steatohepatitis‚ gestational diabetes mellitus‚ significant changes in body eicosanoid status (inflammation)‚ impaired immunity‚ Alzheimer’s disease and certain cancers.
The influence of eicosanoids on glucose and insulin homeostasis has been defined partially‚ but the influence of insulin resistance‚ (or lack) on eicosanoid pathways is not clear. Many individuals with Syndrome X have a dietary status where eicosanoid pathways are driven towards the production of prothrombotic and pro-inflammatory prostaglandins. This may occur largely as a consequence of dietary deficiency of certain
essential fatty acids (Omega-3) or alteration in the ratio of omega 6 and omega 3 essential fatty acid‚ dietary intake. Furthermore‚ there is evidence that eicosanoid production can be modified by insulin lack and hyperglycemia.
Animal studies show increases in a circulating metabolites of PGE2 production after the experimental induction of diabetes with streptozotocin. This rise in PGE2 metabolites is also found in diabetic humans. Thus‚ both of these circumstances can contribute to the development of Syndrome X and insulin resistance. Within the metabolic Syndrome X‚ one may expect to cause changes in the body eicosanoid status in a detrimental manner for health. This metabolic change in eicosanoid status is mainly a quantitative difference in the types of eicosanoid (prostaglandins) produced. More important‚ it is known that among eicosanoid derivatives‚ eicosapentanoic acid (EPA) can enhance insulin sensitivity‚ presumably through effects on PPAR-receptors‚ which regulate the actions of insulin and cholesterol metabolism.
These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose‚ treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious medical condition.
Patented glucolloid‚ beta glucan fraction of oat soluble fiber (7.5g)‚ Chromium polynicotinate (500mcg)‚ Biotin (250mcg)‚ a proprietary blend of alpha lipoic acid‚ guar gum and white kidney bean extract (850mg)‚ Vitamin B6 (2mg)‚ Folic acid (400mcg)‚ Vitamin B12 (6mcg) and Vanadium (50mcg). ADVANTRA Z 65.
Use as directed by a healthcare professional.
Consult a healthcare professional before use.